RxDoctor Payments Data

Joseph Tadros, MD

Dermatology · Evansville, INNPI 1578067096

Payments from drug & device makers

$6,890in general payments, 2019–2025

Across 199 payments — averaging $34.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$831
  • Regeneron Healthcare Solutions, Inc.$794
  • Sanofi$556
  • Galderma Laboratories, L.p.$481
  • Dermavant Sciences, Inc.$302
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,38495%
  • Education$3215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,890 in reported general payments places this provider in the 60th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana

Medicare billing

Part B allowed, 2024
$153,098
Medicare patients
550
Services billed
1,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa27$619,125
Dupixent PenDupilumab30$118,728
OtezlaApremilast20$93,428
Taltz AutoinjectorIxekizumab11$74,763
Dupixent SyringeDupilumab14$51,238
ZoryveRoflumilast21$18,484
Fluorouracil93$6,648
Spinosad23$5,375
Ivermectin33$3,945
Clobetasol Propionate96$3,482
Doxycycline Monohydrate49$3,047
Tacrolimus24$2,633
Ketoconazole162$1,899
Permethrin45$1,603
Fluocinonide12$1,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Arcutis Biotherapeutics, Inc.Zoryve$14$18,48421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 202 dermatology providers in Indiana.

Other dermatology in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →